AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Genetics

Health

AviadoBio Ltd.

More Like This

PR Newswire associated0

Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases

AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Congress

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN

AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial

AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations